Mikael Dolsten exits Pfizer, putting R&D leadership in flux

Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor.Dolsten’s decision will bring to an end a 15-year career at Pfizer which began with the company’s acquisition in 2009 of Wyeth, at which he served as president and head of R&D. A medic by training, he previously had senior roles at Boehringer Ingelheim and AstraZeneca